<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04775615</url>
  </required_header>
  <id_info>
    <org_study_id>DDO-3055-105</org_study_id>
    <nct_id>NCT04775615</nct_id>
  </id_info>
  <brief_title>Multi-dose, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DDO-3055 Tablets in Healthy Subjects.</brief_title>
  <official_title>A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multi-dose DDO-3055 Tablets in Healthy Subjects-Randomized, Double-blind, Dose Escalation, Placebo Controlled Phase I Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is being conducted to evaluate the safety, tolerability, pharmacokinetics and&#xD;
      pharmacodynamics of multi-dose DDO-3055 tablets in healthy subjects for 7 days.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 17, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Multi-dose, dose escalation study in healthy subjects.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with Adverse Events (AE)</measure>
    <time_frame>up to 14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) on Day 1 and Day 7</measure>
    <time_frame>Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma concentration (Cmax) on Day 1 and Day 7</measure>
    <time_frame>Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to maximum plasma concentration (Tmax) on Day 1 and Day 7</measure>
    <time_frame>Pre-dose and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of endogenous erythropoietin from baseline :Day 1 and Day 7</measure>
    <time_frame>0, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VEGF from baseline :Day 1 and Day 7</measure>
    <time_frame>0, 24 hours post dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hb from baseline</measure>
    <time_frame>Day1, Day7, Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Ret from baseline</measure>
    <time_frame>Day1, Day7, Day14</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Hepcidin from baseline</measure>
    <time_frame>Day1, Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Ferritin from baseline</measure>
    <time_frame>Day1, Day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Serum Iron from baseline</measure>
    <time_frame>Day1, Day 9</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Renal Anemia</condition>
  <arm_group>
    <arm_group_label>Treatment group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DDO-3055 tablets；Placebo</intervention_name>
    <description>Low dose：DDO-3055 tablets for 7 days or Placebo for 7 days</description>
    <arm_group_label>Treatment group A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DDO-3055 tablets；Placebo</intervention_name>
    <description>Medium dose：DDO-3055 tablets for 7 days or Placebo for 7 days</description>
    <arm_group_label>Treatment group B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DDO-3055 tablets；Placebo</intervention_name>
    <description>High dose：DDO-3055 tablets for 7 days or Placebo for 7 days</description>
    <arm_group_label>Treatment group C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy volunteers aged 18-45 years;&#xD;
&#xD;
          2. Male weight≥50kg, female weight≥45kg, and 19kg/m2≤BMI≤26kg/m2;&#xD;
&#xD;
          3. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Allergic constitution, suspected to be allergic to the study drug or any component in&#xD;
             the study drug;&#xD;
&#xD;
          2. A value at screening is greater than the upper limit of reference range for the&#xD;
             following clinical laboratory parameters: AST, ALT, Total bilirubin, direct bilirubin,&#xD;
             indirect bilirubin ；&#xD;
&#xD;
          3. Subjects with a value at screening is greater than the upper limit of reference range&#xD;
             for serum creatinine;&#xD;
&#xD;
          4. Subjects with a positive value of HBsAg、HCV-Ab、HIV-Ab、TPPA at screening；&#xD;
&#xD;
          5. Subjects with blood loss ≥400mL within 3 months before screening;&#xD;
&#xD;
          6. Subjects has participated in a clinical trial and has received an investigational&#xD;
             product within 3 months prior to the first dosing day in the current study.&#xD;
&#xD;
          7. Participants who are unwilling to take contraception or male subjects who cannot&#xD;
             guarantee not to donate sperm during the trial and within 30 days after the last dose;&#xD;
             female subjects with fertility who did not use contraception for at least 14 days&#xD;
             before dosing;&#xD;
&#xD;
          8. Patients who had a positive blood pregnancy test and were breastfeeding at the time of&#xD;
             screening.&#xD;
&#xD;
          9. Smokers (average daily smoking 5 or more); Subjects who consumed more than 15 grams of&#xD;
             alcohol per day within one week prior to the screening;&#xD;
&#xD;
         10. Drug abusers or drug urine screening positive;&#xD;
&#xD;
         11. The researchers judged that the subjects had medical conditions that affected the&#xD;
             absorption, distribution, metabolism and excretion of drugs or reduced compliance.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Chang Su</last_name>
    <phone>+86 156 9951 7837</phone>
    <email>suchang@hrglobe.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Junye Xiong</last_name>
    <phone>+86 180 3661 8716</phone>
    <email>xiongjunye@hrglobe.cn</email>
  </overall_contact_backup>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 22, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 1, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

